Khatri Vijay P, Chee Karen G, Petrelli Nicholas J
Division of Surgical Oncology, University of California, Davis Cancer Center, 4501 X Street, Suite 3010, Sacramento, CA 95817, USA.
Surg Oncol. 2007 Jul;16(1):71-83. doi: 10.1016/j.suronc.2007.05.001. Epub 2007 May 29.
Hepatic resection for colorectal metastases, limited to the liver, has become the standard of care, and currently remains the only potentially curative therapy. Numerous single institutional reports have demonstrated long-term survival and there are no other treatment options that have shown a survival plateau. However, curative resection is possible in less than 25% of those patients with disease limited to the liver, which translates into only 5-10% of the original group developing colorectal cancer. To increase the number of patients who could benefit from hepatic resection, the last decade has seen considerable effort being directed towards novel approaches to permit curative hepatic resection such as: neoadjuvant systemic and regional chemotherapy, pre-operative portal vein embolization for hypertrophy of future liver remnant, staged hepatic resection and radio frequency ablation combined with resection for addressing multiple bilobar metastases. This article reviews development of these innovative multidisciplinary modalities and the aggressive surgical approach that has been adopted to extend the frontiers of surgical therapy for colorectal hepatic metastases.
对局限于肝脏的结直肠癌肝转移灶进行肝切除已成为标准治疗方案,并且目前仍然是唯一具有潜在治愈可能的疗法。众多单中心报告已证实了长期生存率,且没有其他治疗方法显示出平台期生存率。然而,在疾病局限于肝脏的患者中,不到25%的患者能够进行根治性切除,这意味着最初患结直肠癌的患者中只有5% - 10%能进行根治性切除。为了增加能够从肝切除中获益的患者数量,在过去十年中,人们付出了巨大努力,致力于采用新方法以实现根治性肝切除,例如:新辅助全身和区域化疗、术前门静脉栓塞以促进未来肝余叶肥大、分期肝切除以及射频消融联合切除以处理多发双侧转移灶。本文回顾了这些创新多学科治疗方式的发展,以及为拓展结直肠癌肝转移手术治疗边界而采用的积极手术方法。